1 Schmiedl Y, Zimmerli S. Tuberkulose: Prävention, Latenz und Multiresistenz. Schweiz Med Forum. 2015;15(41):918–24.
2 Schoch O. Tuberkulose-Update für Allgemeininternisten. Schweiz Med Forum. 2018; 18(26–27):563–68.
3 World Health Organization. Global tuberculosis report 2019. 2019; p. 60.
https://www.who.int/tb/publications/global_report/en/4 Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug- resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):210–360.
5 Sharma A, Hill A, Kurbatova E, van der Walt M, Kvasnovsky C, Tupasi TE, et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. Lancet Infect Dis. 2017;17(7):707–15.
6 Schweizerisches Bundesamt für Gesundheit (BAG), Register TB Fälle, 2020.
7 Walker TM, Merker M, Knoblauch AM, Helbling P, Schoch OD, van der Werf MJ, et al. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. Lancet Infect Dis. 2018;18(4):431–40.
8 Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, et al. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med. 2019;7(9):820–6.
9 Andre E, Goeminne L, Colmant A, Beckert P, Niemann S, Delmee M. Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin- resistance-conferring mutation undetected by commercial assays. Clin Microbiol Infect. 2017;23(4):267.e5–.e7.
10 Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723–32.
11 Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151–60.
12 Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699–706.
13 Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018;52(6).
14 von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Jr., Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249–59.
15 Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet (London, England). 2018;392(10150):821–34.
16 World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019; p. 24.
https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/. 17 Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893–902.
18 Keam SJ. Pretomanid: First Approval. Drugs. 2019;79(16):1797–803.
19 World Health Organization. Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis, 2019.
https://www.who.int/tb/publications/2019/rapid_communications_MDR/en/20 WHO operational handbook on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
https://www.who.int/publications/i/item/978924000699721 Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6):645–62.
22 Schoch OD, Barben J, Berger C, Böttger EC, Egger JM, Fenner L, et al. Tuberculosis in Switzerland. Guidance for Healthcare Professionals. In: Swiss Lung Association SFOoPH, editor. 3. Auflage. Second ed2019.
https://www.tbinfo.ch/wissenszentrum/publikationen/handbuch-tuberkulose.html23 Fox GJ, Nguyen CB, Nguyen TA, Tran PT, Marais BJ, Graham SM, et al. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. BMJ open. 2020;10(1):e033945.
24 Seddon JA, Garcia-Prats AJ, Purchase SE, Osman M, Demers AM, Hoddinott G, et al. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials. 2018;19(1):693.
25 Knight GM, McQuaid CF, Dodd PJ, Houben R. Global burden of latent multidrug- resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis. 2019;19(8):903–12.
26 World Health Organization. The End TB Strategy, 2014.
https://www.who.int/tb/post2015_strategy/en/
27 European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2020 – 2018 data. 2020; p.25.
doi:10.2900/0737073.